首页> 外文OA文献 >Rosiglitazone Treatment Prevents Mitochondrial Dysfunction in Mutant Huntingtin-expressing Cells: POSSIBLE ROLE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-γ (PPARγ) IN THE PATHOGENESIS OF HUNTINGTON DISEASE*
【2h】

Rosiglitazone Treatment Prevents Mitochondrial Dysfunction in Mutant Huntingtin-expressing Cells: POSSIBLE ROLE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-γ (PPARγ) IN THE PATHOGENESIS OF HUNTINGTON DISEASE*

机译:罗格列酮治疗可预防突变体中的线粒体功能障碍 亨廷顿蛋白表达细胞:过氧化物酶的可能作用 增生激活的受体γ(PPARγ)在肺炎的发生中 汉丁顿 疾病*

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Peroxisome proliferator-activated receptor-γ (PPARγ) is a member of the PPAR family of transcription factors. Synthetic PPARγ agonists are used as oral anti-hyperglycemic drugs for the treatment of non-insulin-dependent diabetes. However, emerging evidence indicates that PPARγ activators can also prevent or attenuate neurodegeneration. Given these previous findings, the focus of this report is on the potential neuroprotective role of PPARγ activation in preventing the loss of mitochondrial function in Huntington disease (HD). For these studies we used striatal cells that express wild-type (STHdhQ7/Q7) or mutant (STHdhQ111/Q111) huntingtin protein at physiological levels. Treatment of mutant cells with thapsigargin resulted in a significant decrease in mitochondrial calcium uptake, an increase in reactive oxygen species production, and a significant decrease in mitochondrial membrane potential. PPARγ activation by rosiglitazone prevented the mitochondrial dysfunction and oxidative stress that occurred when mutant striatal cells were challenged with pathological increases in calcium. The beneficial effects of rosiglitazone were likely mediated by activation of PPARγ, as all protective effects were prevented by the PPARγ antagonist GW9662. Additionally, the PPARγ signaling pathway was significantly impaired in the mutant striatal cells with decreases in PPARγ expression and reduced PPARγ transcriptional activity. Treatment with rosiglitazone increased mitochondrial mass levels, suggesting a role for the PPARγ pathway in mitochondrial function in striatal cells. Altogether, this evidence indicates that PPARγ activation by rosiglitazone attenuates mitochondrial dysfunction in mutant huntingtin-expressing striatal cells, and this could be an important therapeutic avenue to ameliorate the mitochondrial dysfunction that occurs in HD.
机译:过氧化物酶体增殖物激活受体-γ(PPARγ)是PPAR转录因子家族的成员。合成的PPARγ激动剂用作口服抗高血糖药物,用于治疗非胰岛素依赖型糖尿病。但是,越来越多的证据表明,PPARγ激活剂也可以预防或减轻神经变性。鉴于这些先前的发现,本报告的重点是PPARγ激活在预防亨廷顿病(HD)线粒体功能丧失中的潜在神经保护作用。对于这些研究,我们使用在生理水平表达野生型(STHdhQ7 / Q7)或突变型(STHdhQ111 / Q111)亨廷顿蛋白的纹状体细胞。用毒胡萝卜素处理突变细胞会导致线粒体钙摄取的显着降低,活性氧的产生增加以及线粒体膜电位的显着降低。罗格列酮激活PPARγ可防止线粒体功能障碍和氧化应激,当突变的纹状体细胞受到钙的病理性增加挑战时发生。罗格列酮的有益作用可能由PPARγ的激活介导,因为所有的保护作用均被PPARγ拮抗剂GW9662阻止。另外,在突变的纹状体细胞中,PPARγ信号传导途径显着受损,PPARγ表达降低且PPARγ转录活性降低。罗格列酮治疗增加了线粒体的质量水平,表明纹状体细胞中PPARγ途径在线粒体功能中的作用。总而言之,该证据表明罗格列酮激活PPARγ可减轻表达亨廷顿蛋白的突变型纹状体细胞中的线粒体功能障碍,这可能是缓解HD中发生的线粒体功能障碍的重要治疗途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号